Jupiter Life Science Consulting Acquires Alta Bioscience Consulting

Jupiter Life Science Consulting Acquires Alta Bioscience Consulting

BOSTON – Dec. 12, 2017 – Jupiter Life Science Consulting, a global leader in market access and pricing strategy in the biopharmaceutical industry, today announced the acquisition of Alta Bioscience Consulting. Alta is a global provider of advisory services in the development and commercialization of bioscience products and organizations. The acquisition supports Jupiter’s rapid geographic expansion and grows its practice areas and payer network in the pharma and biotech industry.

Based in San Francisco, Alta is led by renowned industry leader in pricing and market access, Ted Sweeney, who has a proven track record in clinical and commercial strategy planning. Sweeney specializes in linking evidence development to value demonstration for purposes of funding and utilization, as well as pricing and reimbursement dynamics and strategy. With deep experience and a broad network throughout the health care industry, Sweeney has developed high-impact strategies to bring numerous biopharmaceuticals in rare diseases, oncology and other therapy areas to market.

“This acquisition is a significant event for our company,” said Steve Slovick, CEO and managing partner, Jupiter Life Science Consulting. “With 20 years in the biopharma and biotech industries under his belt, Ted’s expertise and client base is an invaluable addition as Jupiter continues to grow its footprint, client base and staff throughout the U.S., Europe and beyond.”

Following the acquisition, Sweeney will transition to his new role as a managing partner at Jupiter where he will provide senior leadership and continue to assist clients in navigating the fast-evolving market access and reimbursement landscapes.

“Jupiter is a first-class global team of strategy experts with a shared passion for optimizing commercial strategy for pharma and biotech innovators,” said Sweeney. “I couldn’t be more excited to join a group of veterans with this level of experience.”

Slovick added, “We’re committed to providing our clients with the strategic support they need to meet the growing market access demands in the biopharma industry, and to demonstrate and communicate the value of their products. Our joint expertise will help pharmaceutical companies successfully execute development and commercialization strategies.

Jupiter’s acquisition of Alta closed Nov. 8, 2017.